Renaud Ronald C JR — SEC Form 4 filings
SEC reporting owner CIK 1354434. 7 Form 4 filings on record with FilingPulse; latest filed 2026-06-11.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-01-23 to 2026-06-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Cerevel Therapeutics Holdings, Inc. (CERE) | President & CEO, Director | 2 | — | — | 6 |
| Kailera Therapeutics, Inc. (KLRA) | CEO & President, Director | 2 | — | — | 4 |
| Upstream Bio, Inc. (UPB) | Director | 3 | — | — | 3 |
Form 4 filings — Renaud Ronald C JR
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | Kailera Therapeutics, Inc. (KLRA) | Option exercise (M): 38,094 @ $5.25 · Option exercise (M): 38,094 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Upstream Bio, Inc. (UPB) | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Kailera Therapeutics, Inc. (KLRA) | Grant/award (A): 300,000 (derivative) @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Upstream Bio, Inc. (UPB) | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Upstream Bio, Inc. (UPB) | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Cerevel Therapeutics Holdings, Inc. (CERE) | Disposition to issuer (D): 160,452 · Disposition to issuer (D): 83,857 · Disposition to issuer (D): 215,749 (derivative) · Disposition to issuer (D): 284,023 (derivative) @ $0 · Disposition to issuer (D): 320,742 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Cerevel Therapeutics Holdings, Inc. (CERE) | Grant/award (A): 284,023 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1354434 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →